{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T17:34:26Z","timestamp":1793986466631,"version":"4.8.0"},"reference-count":124,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2018,12,4]],"date-time":"2018-12-04T00:00:00Z","timestamp":1543881600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Nephrol"],"published-print":{"date-parts":[[2019,2]]},"DOI":"10.1038\/s41581-018-0087-2","type":"journal-article","created":{"date-parts":[[2018,12,4]],"date-time":"2018-12-04T16:31:54Z","timestamp":1543941114000},"page":"109-120","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":130,"title":["Renal and extrarenal effects of fibroblast growth factor 23"],"prefix":"10.1038","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4607-9415","authenticated-orcid":false,"given":"Marc","family":"Vervloet","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,12,4]]},"reference":[{"key":"87_CR1","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1056\/NEJMoa0810084","volume":"360","author":"FH Schroder","year":"2009","unstructured":"Schroder, F. H. et al. Screening and prostate-cancer mortality in a randomized European study. N. Engl. J. Med. 360, 1320\u20131328 (2009).","journal-title":"N. Engl. J. Med."},{"key":"87_CR2","doi-asserted-by":"crossref","first-page":"3101","DOI":"10.1001\/jama.290.23.3101","volume":"290","author":"LE Boulware","year":"2003","unstructured":"Boulware, L. E., Jaar, B. G., Tarver-Carr, M. E., Brancati, F. L. & Powe, N. R. Screening for proteinuria in US adults: a cost-effectiveness analysis. JAMA 290, 3101\u20133114 (2003).","journal-title":"JAMA"},{"key":"87_CR3","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1681\/ASN.2008060655","volume":"20","author":"M Velde van der","year":"2009","unstructured":"van der Velde, M. et al. Screening for albuminuria identifies individuals at increased renal risk. J. Am. Soc. Nephrol. 20, 852\u2013862 (2009).","journal-title":"J. Am. Soc. Nephrol."},{"key":"87_CR4","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.2215\/CJN.11511114","volume":"10","author":"HJ Lambers Heerspink","year":"2015","unstructured":"Lambers Heerspink, H. J. & Gansevoort, R. T. Albuminuria is an appropriate therapeutic target in patients with CKD: the pro view. Clin. J. Am. Soc. Nephrol. 10, 1079\u20131088 (2015).","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"87_CR5","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1038\/81664","volume":"26","author":"A Consortium","year":"2000","unstructured":"Consortium, A. Autosomal dominant hypophosphataemic rickets is associated with mutations in FGF23. Nat. Genet. 26, 345\u2013348 (2000).","journal-title":"Nat. Genet."},{"key":"87_CR6","doi-asserted-by":"crossref","first-page":"6500","DOI":"10.1073\/pnas.101545198","volume":"98","author":"T Shimada","year":"2001","unstructured":"Shimada, T. et al. Cloning and characterization of FGF23 as a causative factor of tumor-induced osteomalacia. Proc. Natl Acad. Sci. USA 98, 6500\u20136505 (2001).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"87_CR7","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1038\/ki.2011.47","volume":"79","author":"T Isakova","year":"2011","unstructured":"Isakova, T. et al. Fibroblast growth factor 23 is elevated before parathyroid hormone and phosphate in chronic kidney disease. Kidney Int. 79, 1370\u20131378 (2011).","journal-title":"Kidney Int."},{"key":"87_CR8","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/S2213-8587(17)30310-8","volume":"6","author":"A Covic","year":"2018","unstructured":"Covic, A. et al. Bone and mineral disorders in chronic kidney disease: implications for cardiovascular health and ageing in the general population. Lancet Diabetes Endocrinol. 6, 319\u2013331 (2018).","journal-title":"Lancet Diabetes Endocrinol."},{"key":"87_CR9","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1038\/nature05315","volume":"444","author":"I Urakawa","year":"2006","unstructured":"Urakawa, I. et al. Klotho converts canonical FGF receptor into a specific receptor for FGF23. Nature 444, 770\u2013774 (2006).","journal-title":"Nature"},{"key":"87_CR10","doi-asserted-by":"crossref","first-page":"3820","DOI":"10.1172\/JCI36479","volume":"118","author":"LD Quarles","year":"2008","unstructured":"Quarles, L. D. Endocrine functions of bone in mineral metabolism regulation. J. Clin. Invest. 118, 3820\u20133828 (2008).","journal-title":"J. Clin. Invest."},{"key":"87_CR11","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1007\/s00774-011-0343-z","volume":"30","author":"S Osuka","year":"2012","unstructured":"Osuka, S. & Razzaque, M. S. Can features of phosphate toxicity appear in normophosphatemia? J. Bone Miner. Metab. 30, 10\u201318 (2012).","journal-title":"J. Bone Miner. Metab."},{"key":"87_CR12","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1681\/ASN.2008070783","volume":"20","author":"EG Farrow","year":"2009","unstructured":"Farrow, E. G., Davis, S. I., Summers, L. J. & White, K. E. Initial FGF23-mediated signaling occurs in the distal convoluted tubule. J. Am. Soc. Nephrol. 20, 955\u2013960 (2009).","journal-title":"J. Am. Soc. Nephrol."},{"key":"87_CR13","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1359\/JBMR.0301264","volume":"19","author":"T Shimada","year":"2004","unstructured":"Shimada, T. et al. FGF-23 is a potent regulator of vitamin D metabolism and phosphate homeostasis. J. Bone Miner. Res. 19, 429\u2013435 (2004).","journal-title":"J. Bone Miner. Res."},{"key":"87_CR14","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1056\/NEJMoa0706130","volume":"359","author":"OM Gutierrez","year":"2008","unstructured":"Gutierrez, O. M. et al. Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis. N. Engl. J. Med. 359, 584\u2013592 (2008).","journal-title":"N. Engl. J. Med."},{"key":"87_CR15","doi-asserted-by":"crossref","first-page":"189","DOI":"10.3389\/fendo.2018.00189","volume":"9","author":"B Richter","year":"2018","unstructured":"Richter, B. & Faul, C. FGF23 actions on target tissues-with and without Klotho. Front. Endocrinol. 9, 189 (2018).","journal-title":"Front. Endocrinol. (Lausanne)"},{"key":"87_CR16","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.bone.2017.03.043","volume":"100","author":"H Olauson","year":"2017","unstructured":"Olauson, H., Mencke, R., Hillebrands, J. L. & Larsson, T. E. Tissue expression and source of circulating \u03b1Klotho. Bone 100, 19\u201335 (2017).","journal-title":"Bone"},{"key":"87_CR17","doi-asserted-by":"crossref","first-page":"2243","DOI":"10.1161\/CIRCULATIONAHA.111.053405","volume":"125","author":"K Lim","year":"2012","unstructured":"Lim, K. et al. Vascular Klotho deficiency potentiates the development of human artery calcification and mediates resistance to fibroblast growth factor 23. Circulation 125, 2243\u20132255 (2012).","journal-title":"Circulation"},{"key":"87_CR18","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1038\/ki.2013.332","volume":"85","author":"R Jimbo","year":"2014","unstructured":"Jimbo, R. et al. Fibroblast growth factor 23 accelerates phosphate-induced vascular calcification in the absence of Klotho deficiency. Kidney Int. 85, 1103\u20131111 (2014).","journal-title":"Kidney Int."},{"key":"87_CR19","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1093\/cvr\/cvv187","volume":"108","author":"R Mencke","year":"2015","unstructured":"Mencke, R. et al. Membrane-bound Klotho is not expressed endogenously in healthy or uraemic human vascular tissue. Cardiovasc. Res. 108, 220\u2013231 (2015).","journal-title":"Cardiovasc. Res."},{"key":"87_CR20","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1038\/ki.2012.322","volume":"82","author":"WL Lau","year":"2012","unstructured":"Lau, W. L. et al. Vitamin D receptor agonists increase klotho and osteopontin while decreasing aortic calcification in mice with chronic kidney disease fed a high phosphate diet. Kidney Int. 82, 1261\u20131270 (2012).","journal-title":"Kidney Int."},{"key":"87_CR21","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1681\/ASN.2012010048","volume":"23","author":"H Olauson","year":"2012","unstructured":"Olauson, H. et al. Targeted deletion of Klotho in kidney distal tubule disrupts mineral metabolism. J. Am. Soc. Nephrol. 23, 1641\u20131651 (2012).","journal-title":"J. Am. Soc. Nephrol."},{"key":"87_CR22","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.1681\/ASN.2013111209","volume":"25","author":"K Lindberg","year":"2014","unstructured":"Lindberg, K. et al. The kidney is the principal organ mediating klotho effects. J. Am. Soc. Nephrol. 25, 2169\u20132175 (2014).","journal-title":"J. Am. Soc. Nephrol."},{"key":"87_CR23","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1038\/nature25451","volume":"553","author":"G Chen","year":"2018","unstructured":"Chen, G. et al. alpha-Klotho is a non-enzymatic molecular scaffold for FGF23 hormone signalling. Nature 553, 461\u2013466 (2018).","journal-title":"Nature"},{"key":"87_CR24","doi-asserted-by":"crossref","first-page":"3005.1","DOI":"10.1186\/gb-2001-2-3-reviews3005","volume":"2","author":"DM Ornitz","year":"2001","unstructured":"Ornitz, D. M. & Itoh, N. Fibroblast growth factors. Genome Biol. 2, 3005.1\u20133005.12 (2001).","journal-title":"Genome Biol."},{"key":"87_CR25","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1016\/j.cmet.2015.09.002","volume":"22","author":"A Grabner","year":"2015","unstructured":"Grabner, A. et al. Activation of cardiac fibroblast growth factor receptor 4 causes left ventricular hypertrophy. Cell Metab. 22, 1020\u20131032 (2015).","journal-title":"Cell Metab."},{"key":"87_CR26","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1016\/j.kint.2016.05.019","volume":"90","author":"S Singh","year":"2016","unstructured":"Singh, S. et al. Fibroblast growth factor 23 directly targets hepatocytes to promote inflammation in chronic kidney disease. Kidney Int. 90, 985\u2013996 (2016).","journal-title":"Kidney Int."},{"key":"87_CR27","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1172\/JCI83470","volume":"126","author":"J Rossaint","year":"2016","unstructured":"Rossaint, J. et al. FGF23 signaling impairs neutrophil recruitment and host defense during CKD. J. Clin. Invest. 126, 962\u2013974 (2016).","journal-title":"J. Clin. Invest."},{"key":"87_CR28","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1002\/1873-3468.12040","volume":"590","author":"X Han","year":"2016","unstructured":"Han, X. et al. Counter-regulatory paracrine actions of FGF-23 and 1,25(OH)2 D in macrophages. FEBS Lett. 590, 53\u201367 (2016).","journal-title":"FEBS Lett."},{"key":"87_CR29","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1248\/bpb.b14-00276","volume":"38","author":"Y Masuda","year":"2015","unstructured":"Masuda, Y. et al. Expression of Fgf23 in activated dendritic cells and macrophages in response to immunological stimuli in mice. Biol. Pharm. Bull. 38, 687\u2013693 (2015).","journal-title":"Biol. Pharm. Bull."},{"key":"87_CR30","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1002\/jbmr.1740","volume":"28","author":"J Bacchetta","year":"2013","unstructured":"Bacchetta, J. et al. Fibroblast growth factor 23 inhibits extrarenal synthesis of 1,25-dihydroxyvitamin D in human monocytes. J. Bone Miner. Res. 28, 46\u201355 (2013).","journal-title":"J. Bone Miner. Res."},{"key":"87_CR31","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1038\/nrneph.2016.164","volume":"13","author":"MG Vervloet","year":"2017","unstructured":"Vervloet, M. G. et al. The role of phosphate in kidney disease. Nat. Rev. Nephrol. 13, 27\u201338 (2017).","journal-title":"Nat. Rev. Nephrol."},{"key":"87_CR32","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.pbiomolbio.2016.05.010","volume":"122","author":"Z Qi","year":"2016","unstructured":"Qi, Z., Liu, W. & Lu, J. The mechanisms underlying the beneficial effects of exercise on bone remodeling: roles of bone-derived cytokines and microRNAs. Prog. Biophys. Mol. Biol. 122, 131\u2013139 (2016).","journal-title":"Prog. Biophys. Mol. Biol."},{"key":"87_CR33","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1111\/j.1749-6632.2009.05243.x","volume":"1192","author":"S Temiyasathit","year":"2010","unstructured":"Temiyasathit, S. & Jacobs, C. R. Osteocyte primary cilium and its role in bone mechanotransduction. Ann. NY Acad. Sci. 1192, 422\u2013428 (2010).","journal-title":"Ann. NY Acad. Sci."},{"key":"87_CR34","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1002\/emmm.201303716","volume":"6","author":"O Andrukhova","year":"2014","unstructured":"Andrukhova, O. et al. FGF23 regulates renal sodium handling and blood pressure. EMBO Mol. Med. 6, 744\u2013759 (2014).","journal-title":"EMBO Mol. Med."},{"key":"87_CR35","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1677\/JOE-07-0267","volume":"195","author":"T Krajisnik","year":"2007","unstructured":"Krajisnik, T. et al. Fibroblast growth factor-23 regulates parathyroid hormone and 1alpha-hydroxylase expression in cultured bovine parathyroid cells. J. Endocrinol. 195, 125\u2013131 (2007).","journal-title":"J. Endocrinol."},{"key":"87_CR36","first-page":"4003","volume":"117","author":"IZ Ben-Dov","year":"2007","unstructured":"Ben-Dov, I. Z. et al. The parathyroid is a target organ for FGF23 in rats. J. Clin. Invest. 117, 4003\u20134008 (2007).","journal-title":"J. Clin. Invest."},{"key":"87_CR37","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pgen.1003975","volume":"9","author":"H Olauson","year":"2013","unstructured":"Olauson, H. et al. Parathyroid-specific deletion of Klotho unravels a novel calcineurin-dependent FGF23 signaling pathway that regulates PTH secretion. PLOS Genet. 9, e1003975 (2013).","journal-title":"PLOS Genet."},{"key":"87_CR38","doi-asserted-by":"crossref","DOI":"10.1038\/srep40534","volume":"7","author":"K Kawakami","year":"2017","unstructured":"Kawakami, K. et al. Persistent fibroblast growth factor 23 signalling in the parathyroid glands for secondary hyperparathyroidism in mice with chronic kidney disease. Sci. Rep. 7, 40534 (2017).","journal-title":"Sci. Rep."},{"key":"87_CR39","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1038\/ki.2009.464","volume":"77","author":"H Galitzer","year":"2010","unstructured":"Galitzer, H., Ben-Dov, I. Z., Silver, J. & Naveh-Many, T. Parathyroid cell resistance to fibroblast growth factor 23 in secondary hyperparathyroidism of chronic kidney disease. Kidney Int. 77, 211\u2013218 (2010).","journal-title":"Kidney Int."},{"key":"87_CR40","doi-asserted-by":"crossref","first-page":"1987","DOI":"10.1056\/NEJMoa1714641","volume":"378","author":"TO Carpenter","year":"2018","unstructured":"Carpenter, T. O. et al. Burosumab therapy in children with X-linked hypophosphatemia. N. Engl. J. Med. 378, 1987\u20131998 (2018).","journal-title":"N. Engl. J. Med."},{"key":"87_CR41","doi-asserted-by":"crossref","first-page":"2543","DOI":"10.1172\/JCI61405","volume":"122","author":"V Shalhoub","year":"2012","unstructured":"Shalhoub, V. et al. FGF23 neutralization improves chronic kidney disease-associated hyperparathyroidism yet increases mortality. J. Clin. Invest. 122, 2543\u20132553 (2012).","journal-title":"J. Clin. Invest."},{"key":"87_CR42","doi-asserted-by":"crossref","first-page":"2015","DOI":"10.1681\/ASN.2017121334","volume":"29","author":"A Marthi","year":"2018","unstructured":"Marthi, A. et al. Fibroblast growth factor-23 and risks of cardiovascular and noncardiovascular diseases: a meta-analysis. J. Am. Soc. Nephrol. 29, 2015\u20132027 (2018).","journal-title":"J. Am. Soc. Nephrol."},{"key":"87_CR43","doi-asserted-by":"crossref","first-page":"2432","DOI":"10.1001\/jama.2011.826","volume":"305","author":"T Isakova","year":"2011","unstructured":"Isakova, T. et al. Fibroblast growth factor 23 and risks of mortality and end-stage renal disease in patients with chronic kidney disease. JAMA 305, 2432\u20132439 (2011).","journal-title":"JAMA"},{"key":"87_CR44","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.bbrc.2012.07.045","volume":"425","author":"K Ikeda","year":"2012","unstructured":"Ikeda, K. et al. Macrophages play a unique role in the plaque calcification by enhancing the osteogenic signals exerted by vascular smooth muscle cells. Biochem. Biophys. Res. Commun. 425, 39\u201344 (2012).","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"87_CR45","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1681\/ASN.2016040401","volume":"28","author":"KL Nowak","year":"2017","unstructured":"Nowak, K. L. et al. Fibroblast growth factor 23 and the risk of infection-related hospitalization in older adults. J. Am. Soc. Nephrol. 28, 1239\u20131246 (2017).","journal-title":"J. Am. Soc. Nephrol."},{"key":"87_CR46","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1001\/jamacardio.2016.1445","volume":"1","author":"R Mehta","year":"2016","unstructured":"Mehta, R. et al. Association of fibroblast growth factor 23 with atrial fibrillation in chronic kidney disease, from the chronic renal insufficiency cohort study. JAMA Cardiol. 1, 548\u2013556 (2016).","journal-title":"JAMA Cardiol."},{"key":"87_CR47","doi-asserted-by":"crossref","first-page":"531","DOI":"10.2215\/CJN.10810917","volume":"13","author":"DE Leaf","year":"2018","unstructured":"Leaf, D. E. et al. Fibroblast growth factor 23 associates with death in critically ill patients. Clin. J. Am. Soc. Nephrol. 13, 531\u2013541 (2018).","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"87_CR48","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1681\/ASN.2017070772","volume":"29","author":"T Isakova","year":"2018","unstructured":"Isakova, T. et al. Longitudinal FGF23 trajectories and mortality in patients with CKD. J. Am. Soc. Nephrol. 29, 579\u2013590 (2018).","journal-title":"J. Am. Soc. Nephrol."},{"key":"87_CR49","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1080\/07435800.2016.1242604","volume":"42","author":"Y Takashi","year":"2017","unstructured":"Takashi, Y. et al. Patients with FGF23-related hypophosphatemic rickets\/osteomalacia do not present with left ventricular hypertrophy. Endocr. Res. 42, 132\u2013137 (2017).","journal-title":"Endocr. Res."},{"key":"87_CR50","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1097\/MAJ.0b013e3181815498","volume":"337","author":"HJ Hsu","year":"2009","unstructured":"Hsu, H. J. & Wu, M. S. Fibroblast growth factor 23: a possible cause of left ventricular hypertrophy in hemodialysis patients. Am. J. Med. Sci. 337, 116\u2013122 (2009).","journal-title":"Am. J. Med. Sci."},{"key":"87_CR51","doi-asserted-by":"crossref","first-page":"135","DOI":"10.5414\/CN108716","volume":"85","author":"M Sarmento-Dias","year":"2016","unstructured":"Sarmento-Dias, M. et al. Fibroblast growth factor 23 is associated with left ventricular hypertrophy, not with uremic vasculopathy in peritoneal dialysis patients. Clin. Nephrol. 85, 135\u2013141 (2016).","journal-title":"Clin. Nephrol."},{"key":"87_CR52","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1016\/j.atherosclerosis.2009.05.013","volume":"207","author":"MA Mirza","year":"2009","unstructured":"Mirza, M. A., Larsson, A., Melhus, H., Lind, L. & Larsson, T. E. Serum intact FGF23 associate with left ventricular mass, hypertrophy and geometry in an elderly population. Atherosclerosis 207, 546\u2013551 (2009).","journal-title":"Atherosclerosis"},{"key":"87_CR53","doi-asserted-by":"crossref","first-page":"4393","DOI":"10.1172\/JCI46122","volume":"121","author":"C Faul","year":"2011","unstructured":"Faul, C. et al. FGF23 induces left ventricular hypertrophy. J. Clin. Invest. 121, 4393\u20134408 (2011).","journal-title":"J. Clin. Invest."},{"key":"87_CR54","doi-asserted-by":"crossref","first-page":"45","DOI":"10.2215\/CJN.02110217","volume":"13","author":"MM Mitsnefes","year":"2018","unstructured":"Mitsnefes, M. M. et al. FGF23 and left ventricular hypertrophy in children with CKD. Clin. J. Am. Soc. Nephrol. 13, 45\u201352 (2018).","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"87_CR55","doi-asserted-by":"crossref","first-page":"1843","DOI":"10.1007\/s00467-015-3125-3","volume":"30","author":"MD Sinha","year":"2015","unstructured":"Sinha, M. D. et al. Relationship of FGF23 to indexed left ventricular mass in children with non-dialysis stages of chronic kidney disease. Pediatr. Nephrol. 30, 1843\u20131852 (2015).","journal-title":"Pediatr. Nephrol."},{"key":"87_CR56","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1159\/000339026","volume":"36","author":"A Unsal","year":"2012","unstructured":"Unsal, A. et al. Relationship of fibroblast growth factor 23 with left ventricle mass index and coronary calcificaton in chronic renal disease. Kidney Blood Press Res. 36, 55\u201364 (2012).","journal-title":"Kidney Blood Press Res."},{"key":"87_CR57","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.atherosclerosis.2013.09.002","volume":"231","author":"A Jovanovich","year":"2013","unstructured":"Jovanovich, A. et al. Fibroblast growth factor 23, left ventricular mass, and left ventricular hypertrophy in community-dwelling older adults. Atherosclerosis 231, 114\u2013119 (2013).","journal-title":"Atherosclerosis"},{"key":"87_CR58","doi-asserted-by":"crossref","DOI":"10.1371\/annotation\/13086f84-18f2-4ea3-881a-0484b0c411ee","volume":"8","author":"K Shibata","year":"2013","unstructured":"Shibata, K. et al. Association between circulating fibroblast growth factor 23, alpha-Klotho, and the left ventricular ejection fraction and left ventricular mass in cardiology inpatients. PLOS ONE 8, e73184 (2013).","journal-title":"PLOS ONE"},{"key":"87_CR59","volume":"11","author":"S Tanaka","year":"2016","unstructured":"Tanaka, S., Fujita, S., Kizawa, S., Morita, H. & Ishizaka, N. Association between FGF23, alpha-Klotho, and cardiac abnormalities among patients with various chronic kidney disease stages. PLOS ONE 11, e0156860 (2016).","journal-title":"PLOS ONE"},{"key":"87_CR60","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-017-02068-6","volume":"7","author":"A Grabner","year":"2017","unstructured":"Grabner, A. et al. FGF23\/FGFR4-mediated left ventricular hypertrophy is reversible. Sci. Rep. 7, 1993 (2017).","journal-title":"Sci. Rep."},{"key":"87_CR61","doi-asserted-by":"crossref","DOI":"10.14814\/phy2.13591","volume":"6","author":"M Verkaik","year":"2018","unstructured":"Verkaik, M. et al. High fibroblast growth factor 23 concentrations in experimental renal failure impair calcium handling in cardiomyocytes. Physiol. Rep. 6, e13591 (2018).","journal-title":"Physiol. Rep."},{"key":"87_CR62","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1007\/s10554-013-0337-0","volume":"30","author":"R Wald","year":"2014","unstructured":"Wald, R. et al. Correlates of left ventricular mass in chronic hemodialysis recipients. Int. J. Cardiovasc. Imag. 30, 349\u2013356 (2014).","journal-title":"Int. J. Cardiovasc. Imag."},{"key":"87_CR63","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1515\/jtim-2016-0030","volume":"4","author":"AA Nassiri","year":"2016","unstructured":"Nassiri, A. A. et al. Association of serum intact fibroblast growth factor 23 with left ventricular mass and different echocardiographic findings in patients on hemodialysis. J. Transl Int. Med. 4, 135\u2013141 (2016).","journal-title":"J. Transl Int. Med."},{"key":"87_CR64","doi-asserted-by":"crossref","first-page":"2165","DOI":"10.1210\/en.2018-00174","volume":"159","author":"ES Liu","year":"2018","unstructured":"Liu, E. S. et al. Increased circulating FGF23 does not lead to cardiac hypertrophy in the male hyp mouse model of XLH. Endocrinology 159, 2165\u20132172 (2018).","journal-title":"Endocrinology"},{"key":"87_CR65","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.kint.2018.02.017","volume":"94","author":"EM Pastor-Arroyo","year":"2018","unstructured":"Pastor-Arroyo, E. M. et al. The elevation of circulating fibroblast growth factor 23 without kidney disease does not increase cardiovascular disease risk. Kidney Int. 94, 49\u201359 (2018).","journal-title":"Kidney Int."},{"key":"87_CR66","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.kint.2018.03.024","volume":"94","author":"C Faul","year":"2018","unstructured":"Faul, C. FGF23 effects on the heart-levels, time, source, and context matter. Kidney Int. 94, 7\u201311 (2018).","journal-title":"Kidney Int."},{"key":"87_CR67","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1093\/ndt\/gfm672","volume":"23","author":"R Marsell","year":"2008","unstructured":"Marsell, R. et al. Gene expression analysis of kidneys from transgenic mice expressing fibroblast growth factor-23. Nephrol. Dial. Transplant. 23, 827\u2013833 (2008).","journal-title":"Nephrol. Dial. Transplant."},{"key":"87_CR68","volume":"3","author":"J Xie","year":"2012","unstructured":"Xie, J. et al. Cardioprotection by Klotho through downregulation of TRPC6 channels in the mouse heart. Nat. Commun. 3, 1238 (2012).","journal-title":"Nat. Commun."},{"key":"87_CR69","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1681\/ASN.2014040325","volume":"26","author":"J Xie","year":"2015","unstructured":"Xie, J., Yoon, J., An, S. W., Kuro-o M. & Huang, C. L. Soluble klotho protects against uremic cardiomyopathy independently of fibroblast growth factor 23 and phosphate. J. Am. Soc. Nephrol. 26, 1150\u20131160 (2015).","journal-title":"J. Am. Soc. Nephrol."},{"key":"87_CR70","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1093\/ndt\/gfw454","volume":"32","author":"M Leifheit-Nestler","year":"2017","unstructured":"Leifheit-Nestler, M. et al. Vitamin D treatment attenuates cardiac FGF23\/FGFR4 signaling and hypertrophy in uremic rats. Nephrol. Dial. Transplant. 32, 1493\u20131503 (2017).","journal-title":"Nephrol. Dial. Transplant."},{"key":"87_CR71","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-017-10140-4","volume":"7","author":"S Slavic","year":"2017","unstructured":"Slavic, S. et al. Genetic ablation of Fgf23 or klotho does not modulate experimental heart hypertrophy induced by pressure overload. Sci. Rep. 7, 11298 (2017).","journal-title":"Sci. Rep."},{"key":"87_CR72","doi-asserted-by":"crossref","first-page":"1831","DOI":"10.1002\/jbmr.2527","volume":"30","author":"O Andrukhova","year":"2015","unstructured":"Andrukhova, O., Slavic, S., Odorfer, K. I. & Erben, R. G. Experimental myocardial infarction upregulates circulating fibroblast growth factor 23. J. Bone Miner. Res. 30, 1831\u20131839 (2015).","journal-title":"J. Bone Miner. Res."},{"key":"87_CR73","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.kint.2018.02.018","volume":"94","author":"I Matsui","year":"2018","unstructured":"Matsui, I. et al. Cardiac hypertrophy elevates serum levels of fibroblast growth factor 23. Kidney Int. 94, 60\u201371 (2018).","journal-title":"Kidney Int."},{"key":"87_CR74","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1093\/ndt\/gfv398","volume":"31","author":"IA Andersen","year":"2016","unstructured":"Andersen, I. A. et al. Elevation of circulating but not myocardial FGF23 in human acute decompensated heart failure. Nephrol. Dial. Transplant. 31, 767\u2013772 (2016).","journal-title":"Nephrol. Dial. Transplant."},{"key":"87_CR75","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1016\/j.kint.2015.12.035","volume":"89","author":"DE Leaf","year":"2016","unstructured":"Leaf, D. E. et al. Fibroblast growth factor 23 levels are elevated and associated with severe acute kidney injury and death following cardiac surgery. Kidney Int. 89, 939\u2013948 (2016).","journal-title":"Kidney Int."},{"key":"87_CR76","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.bonr.2017.01.003","volume":"6","author":"JM Hum","year":"2017","unstructured":"Hum, J. M. et al. The metabolic bone disease associated with the Hyp mutation is independent of osteoblastic HIF1alpha expression. Bone Rep. 6, 38\u201343 (2017).","journal-title":"Bone Rep."},{"key":"87_CR77","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0186979","volume":"12","author":"I Flamme","year":"2017","unstructured":"Flamme, I., Ellinghaus, P., Urrego, D. & Kruger, T. FGF23 expression in rodents is directly induced via erythropoietin after inhibition of hypoxia inducible factor proline hydroxylase. PLOS ONE 12, e0186979 (2017).","journal-title":"PLOS ONE"},{"key":"87_CR78","doi-asserted-by":"crossref","first-page":"2421","DOI":"10.1016\/j.jacc.2014.03.026","volume":"63","author":"JA Udell","year":"2014","unstructured":"Udell, J. A. et al. Fibroblast growth factor-23, cardiovascular prognosis, and benefit of angiotensin-converting enzyme inhibition in stable ischemic heart disease. J. Am. Coll. Cardiol. 63, 2421\u20132428 (2014).","journal-title":"J. Am. Coll. Cardiol."},{"key":"87_CR79","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1016\/j.kint.2016.09.024","volume":"91","author":"M Vervloet","year":"2016","unstructured":"Vervloet, M. & Cozzolino, M. Vascular calcification in chronic kidney disease: different bricks in the wall? Kidney Int. 91, 808\u2013817 (2016).","journal-title":"Kidney Int."},{"key":"87_CR80","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1038\/ki.2013.3","volume":"83","author":"JJ Scialla","year":"2013","unstructured":"Scialla, J. J. et al. Fibroblast growth factor 23 is not associated with and does not induce arterial calcification. Kidney Int. 83, 1159\u20131168 (2013).","journal-title":"Kidney Int."},{"key":"87_CR81","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1681\/ASN.2013050465","volume":"25","author":"JJ Scialla","year":"2014","unstructured":"Scialla, J. J. et al. Fibroblast growth factor-23 and cardiovascular events in CKD. J. Am. Soc. Nephrol. 25, 349\u2013360 (2014).","journal-title":"J. Am. Soc. Nephrol."},{"key":"87_CR82","doi-asserted-by":"crossref","first-page":"2679","DOI":"10.1093\/ndt\/gfq089","volume":"25","author":"MM Nasrallah","year":"2010","unstructured":"Nasrallah, M. M. et al. Fibroblast growth factor-23 (FGF-23) is independently correlated to aortic calcification in haemodialysis patients. Nephrol. Dial. Transplant. 25, 2679\u20132685 (2010).","journal-title":"Nephrol. Dial. Transplant."},{"key":"87_CR83","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1093\/cvr\/cvv228","volume":"108","author":"C Faul","year":"2015","unstructured":"Faul, C. & Wolf, M. Hunt for the culprit of cardiovascular injury in kidney disease. Cardiovasc. Res. 108, 209\u2013211 (2015).","journal-title":"Cardiovasc. Res."},{"key":"87_CR84","volume":"8","author":"K Lindberg","year":"2013","unstructured":"Lindberg, K. et al. Arterial klotho expression and FGF23 effects on vascular calcification and function. PLOS ONE 8, e60658 (2013).","journal-title":"PLOS ONE"},{"key":"87_CR85","doi-asserted-by":"crossref","first-page":"3125","DOI":"10.1093\/ndt\/gfp205","volume":"24","author":"MA Mirza","year":"2009","unstructured":"Mirza, M. A. et al. Relationship between circulating FGF23 and total body atherosclerosis in the community. Nephrol. Dial. Transplant. 24, 3125\u20133131 (2009).","journal-title":"Nephrol. Dial. Transplant."},{"key":"87_CR86","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/j.atherosclerosis.2009.01.001","volume":"205","author":"MA Mirza","year":"2009","unstructured":"Mirza, M. A., Larsson, A., Lind, L. & Larsson, T. E. Circulating fibroblast growth factor-23 is associated with vascular dysfunction in the community. Atherosclerosis 205, 385\u2013390 (2009).","journal-title":"Atherosclerosis"},{"key":"87_CR87","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.116.003486","volume":"5","author":"R Haring","year":"2016","unstructured":"Haring, R. et al. Plasma fibroblast growth factor 23: clinical correlates and association with cardiovascular disease and mortality in the framingham heart study. J. Am. Heart Assoc. 5, e003486 (2016).","journal-title":"J. Am. Heart Assoc."},{"key":"87_CR88","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1038\/ki.2010.194","volume":"78","author":"MI Yilmaz","year":"2010","unstructured":"Yilmaz, M. I. et al. FGF-23 and vascular dysfunction in patients with stage 3 and 4 chronic kidney disease. Kidney Int. 78, 679\u2013685 (2010).","journal-title":"Kidney Int."},{"key":"87_CR89","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1681\/ASN.2013121355","volume":"26","author":"G Tripepi","year":"2015","unstructured":"Tripepi, G. et al. Competitive interaction between fibroblast growth factor 23 and asymmetric dimethylarginine in patients with CKD. J. Am. Soc. Nephrol. 26, 935\u2013944 (2015).","journal-title":"J. Am. Soc. Nephrol."},{"key":"87_CR90","volume":"9","author":"I Six","year":"2014","unstructured":"Six, I. et al. Direct, acute effects of Klotho and FGF23 on vascular smooth muscle and endothelium. PLOS ONE 9, e93423 (2014).","journal-title":"PLOS ONE"},{"key":"87_CR91","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1007\/s00424-016-1858-x","volume":"468","author":"B Richter","year":"2016","unstructured":"Richter, B., Haller, J., Haffner, D. & Leifheit-Nestler, M. Klotho modulates FGF23-mediated NO synthesis and oxidative stress in human coronary artery endothelial cells. Pflugers Arch. 468, 1621\u20131635 (2016).","journal-title":"Pflugers Arch."},{"key":"87_CR92","doi-asserted-by":"crossref","first-page":"E426","DOI":"10.1152\/ajpendo.00264.2014","volume":"307","author":"N Silswal","year":"2014","unstructured":"Silswal, N. et al. FGF23 directly impairs endothelium-dependent vasorelaxation by increasing superoxide levels and reducing nitric oxide bioavailability. Am. J. Physiol. Endocrinol. Metab. 307, E426\u2013E436 (2014).","journal-title":"Am. J. Physiol. Endocrinol. Metab."},{"key":"87_CR93","doi-asserted-by":"crossref","first-page":"H1414","DOI":"10.1152\/ajpheart.00272.2018","volume":"315","author":"M Verkaik","year":"2018","unstructured":"Verkaik, M. et al. FGF23 impairs peripheral microvascular function in renal failure. Am. J. Physiol. Heart Circ. Physiol. 315, H1414\u2013H1424 (2018).","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"key":"87_CR94","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1093\/eurheartj\/ehu403","volume":"36","author":"JC Mason","year":"2015","unstructured":"Mason, J. C. & Libby, P. Cardiovascular disease in patients with chronic inflammation: mechanisms underlying premature cardiovascular events in rheumatologic conditions. Eur. Heart J. 36, 482\u2013489 (2015).","journal-title":"Eur. Heart J."},{"key":"87_CR95","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.2215\/CJN.13281211","volume":"7","author":"J Munoz Mendoza","year":"2012","unstructured":"Munoz Mendoza, J. et al. Fibroblast growth factor 23 and Inflammation in CKD. Clin. J. Am. Soc. Nephrol. 7, 1155\u20131162 (2012).","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"87_CR96","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.mce.2014.10.007","volume":"399","author":"N Ito","year":"2015","unstructured":"Ito, N. et al. Regulation of FGF23 expression in IDG-SW3 osteocytes and human bone by pro-inflammatory stimuli. Mol. Cell Endocrinol. 399, 208\u2013218 (2015).","journal-title":"Mol. Cell Endocrinol."},{"key":"87_CR97","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1007\/s00223-016-0116-8","volume":"98","author":"JL Pathak","year":"2016","unstructured":"Pathak, J. L. et al. Systemic inflammation affects human osteocyte-specific protein and cytokine expression. Calcif. Tissue Int. 98, 596\u2013608 (2016).","journal-title":"Calcif. Tissue Int."},{"key":"87_CR98","first-page":"269","volume":"14","author":"SH Durlacher","year":"1942","unstructured":"Durlacher, S. H. & Winternitz, M. C. Studies on the relation of the kidney to cardiovascular disease: V. lesions of the myocardium. 14, 269\u2013278 (1942).","journal-title":"lesions of the myocardium."},{"key":"87_CR99","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1038\/ki.2015.290","volume":"89","author":"V David","year":"2016","unstructured":"David, V. et al. Inflammation and functional iron deficiency regulate fibroblast growth factor 23 production. Kidney Int. 89, 135\u2013146 (2016).","journal-title":"Kidney Int."},{"key":"87_CR100","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1016\/j.kint.2016.08.013","volume":"90","author":"M Hanudel","year":"2016","unstructured":"Hanudel, M., Juppner, H. & Salusky, I. B. Fibroblast growth factor 23: fueling the fire. Kidney Int. 90, 928\u2013930 (2016).","journal-title":"Kidney Int."},{"key":"87_CR101","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1016\/j.kint.2016.10.021","volume":"91","author":"J Munoz Mendoza","year":"2017","unstructured":"Munoz Mendoza, J. et al. Inflammation and elevated levels of fibroblast growth factor 23 are independent risk factors for death in chronic kidney disease. Kidney Int. 91, 711\u2013719 (2017).","journal-title":"Kidney Int."},{"key":"87_CR102","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1056\/NEJMoa041031","volume":"351","author":"AS Go","year":"2004","unstructured":"Go, A. S., Chertow, G. M., Fan, D., McCulloch, C. E. & Hsu, C. Y. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N. Engl. J. Med. 351, 1296\u20131305 (2004).","journal-title":"N. Engl. J. Med."},{"key":"87_CR103","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1038\/nrneph.2014.8","volume":"10","author":"DJ Jager de","year":"2014","unstructured":"de Jager, D. J., Vervloet, M. G. & Dekker, F. W. Noncardiovascular mortality in CKD: an epidemiological perspective. Nat. Rev. Nephrol. 10, 208\u2013214 (2014).","journal-title":"Nat. Rev. Nephrol."},{"key":"87_CR104","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1681\/ASN.2014101009","volume":"27","author":"M Chonchol","year":"2016","unstructured":"Chonchol, M., Greene, T., Zhang, Y., Hoofnagle, A. N. & Cheung, A. K. Low vitamin D and high fibroblast growth factor 23 serum levels associate with infectious and cardiac deaths in the HEMO study. J. Am. Soc. Nephrol. 27, 227\u2013237 (2016).","journal-title":"J. Am. Soc. Nephrol."},{"key":"87_CR105","doi-asserted-by":"crossref","first-page":"4648","DOI":"10.1210\/jc.2017-01868","volume":"102","author":"J Ishigami","year":"2017","unstructured":"Ishigami, J. et al. Biomarkers of mineral and bone metabolism and 20-year risk of hospitalization with infection: the atherosclerosis risk in communities study. J. Clin. Endocrinol. Metab. 102, 4648\u20134657 (2017).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"87_CR106","doi-asserted-by":"crossref","first-page":"3773","DOI":"10.1182\/blood-2007-06-094565","volume":"110","author":"A Zarbock","year":"2007","unstructured":"Zarbock, A., Deem, T. L., Burcin, T. L. & Ley, K. G\u03b1i2 is required for chemokine-induced neutrophil arrest. Blood 110, 3773\u20133779 (2007).","journal-title":"Blood"},{"key":"87_CR107","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/978-1-4614-0887-1_1","volume":"728","author":"A Beenken","year":"2012","unstructured":"Beenken, A. & Mohammadi, M. The structural biology of the FGF19 subfamily. Adv. Exp. Med. Biol. 728, 1\u201324 (2012).","journal-title":"Adv. Exp. Med. Biol."},{"key":"87_CR108","doi-asserted-by":"crossref","first-page":"320","DOI":"10.3389\/fendo.2018.00320","volume":"9","author":"EA Fitzpatrick","year":"2018","unstructured":"Fitzpatrick, E. A., Han, X., Xiao, Z. & Quarles, L. D. Role of fibroblast growth factor-23 in innate immune responses. Front. Endocrinol. 9, 320 (2018).","journal-title":"Front. Endocrinol. (Lausanne)"},{"key":"87_CR109","doi-asserted-by":"crossref","first-page":"2663","DOI":"10.3390\/ijms19092663","volume":"19","author":"M Medrano","year":"2018","unstructured":"Medrano, M., Carrillo-Cruz, E., Montero, I. & Perez-Simon, J. A. Vitamin D: effect on haematopoiesis and immune system and clinical applications. Int. J. Mol. Sci. 19, 2663 (2018).","journal-title":"Int. J. Mol. Sci."},{"key":"87_CR110","first-page":"5624","volume":"44","author":"HP Koeffler","year":"1984","unstructured":"Koeffler, H. P., Amatruda, T., Ikekawa, N., Kobayashi, Y. & DeLuca, H. F. Induction of macrophage differentiation of human normal and leukemic myeloid stem cells by 1,25-dihydroxyvitamin D3 and its fluorinated analogues. Cancer Res. 44, 5624\u20135628 (1984).","journal-title":"Cancer Res."},{"key":"87_CR111","doi-asserted-by":"crossref","first-page":"1770","DOI":"10.1126\/science.1123933","volume":"311","author":"PT Liu","year":"2006","unstructured":"Liu, P. T. et al. Toll-like receptor triggering of a vitamin D-mediated human antimicrobial response. Science 311, 1770\u20131773 (2006).","journal-title":"Science"},{"key":"87_CR112","doi-asserted-by":"crossref","first-page":"1795","DOI":"10.2215\/CJN.03950417","volume":"12","author":"R Mehta","year":"2017","unstructured":"Mehta, R. et al. Fibroblast growth factor 23 and anemia in the chronic renal insufficiency cohort study. Clin. J. Am. Soc. Nephrol. 12, 1795\u20131803 (2017).","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"87_CR113","doi-asserted-by":"crossref","first-page":"9795","DOI":"10.1074\/jbc.M113.527150","volume":"289","author":"LM Coe","year":"2014","unstructured":"Coe, L. M. et al. FGF-23 is a negative regulator of prenatal and postnatal erythropoiesis. J. Biol. Chem. 289, 9795\u20139810 (2014).","journal-title":"J. Biol. Chem."},{"key":"87_CR114","doi-asserted-by":"crossref","first-page":"3752","DOI":"10.1096\/fj.201700667R","volume":"32","author":"R Agoro","year":"2018","unstructured":"Agoro, R. et al. Inhibition of fibroblast growth factor 23 (FGF23) signaling rescues renal anemia. FASEB J. 32, 3752\u20133764 (2018).","journal-title":"FASEB J."},{"key":"87_CR115","doi-asserted-by":"crossref","first-page":"125","DOI":"10.2147\/IJNRD.S158422","volume":"11","author":"M Yashiro","year":"2018","unstructured":"Yashiro, M. et al. FGF23 modulates the effects of erythropoietin on gene expression in renal epithelial cells. Int. J. Nephrol. Renovasc Dis. 11, 125\u2013136 (2018).","journal-title":"Int. J. Nephrol. Renovasc Dis."},{"key":"87_CR116","doi-asserted-by":"crossref","first-page":"383","DOI":"10.2215\/CJN.04730510","volume":"6","author":"MG Vervloet","year":"2011","unstructured":"Vervloet, M. G. et al. Effects of dietary phosphate and calcium intake on fibroblast growth factor-23. Clin. J. Am. Soc. Nephrol. 6, 383\u2013389 (2011).","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"87_CR117","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1210\/jc.2004-1039","volume":"90","author":"SL Ferrari","year":"2005","unstructured":"Ferrari, S. L., Bonjour, J. P. & Rizzoli, R. Fibroblast growth factor-23 relationship to dietary phosphate and renal phosphate handling in healthy young men. J. Clin. Endocrinol. Metab. 90, 1519\u20131524 (2005).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"87_CR118","doi-asserted-by":"publisher","unstructured":"Tsai, W. C. et al. Effects of lower versus higher phosphate diets on fibroblast growth factor-23 levels in patients with chronic kidney disease: a systematic review and meta-analysis. Nephrol. Dial. Transplant. \n                    https:\/\/doi.org\/10.1093\/ndt\/gfy005\n                    \n                   (2018).","DOI":"10.1093\/ndt\/gfy005"},{"key":"87_CR119","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfy127","author":"M Ketteler","year":"2018","unstructured":"Ketteler, M. et al. Effects of sucroferric oxyhydroxide and sevelamer carbonate on chronic kidney disease-mineral bone disorder parameters in dialysis patients. Nephrol. Dial. Transplant. \n                    https:\/\/doi.org\/10.1093\/ndt\/gfy127\n                    \n                   (2018).","journal-title":"Nephrol. Dial. Transplant."},{"key":"87_CR120","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1093\/ndt\/gfr384","volume":"27","author":"M Koizumi","year":"2012","unstructured":"Koizumi, M., Komaba, H., Nakanishi, S., Fujimori, A. & Fukagawa, M. Cinacalcet treatment and serum FGF23 levels in haemodialysis patients with secondary hyperparathyroidism. Nephrol. Dial. Transplant. 27, 784\u2013790 (2012).","journal-title":"Nephrol. Dial. Transplant."},{"key":"87_CR121","doi-asserted-by":"crossref","first-page":"110","DOI":"10.2215\/CJN.03630509","volume":"5","author":"JB Wetmore","year":"2010","unstructured":"Wetmore, J. B., Liu, S., Krebill, R., Menard, R. & Quarles, L. D. Effects of cinacalcet and concurrent low-dose vitamin D on FGF23 levels in ESRD. Clin J. Am. Soc. Nephrol. 5, 110\u2013116 (2010).","journal-title":"Clin J. Am. Soc. Nephrol."},{"key":"87_CR122","doi-asserted-by":"crossref","first-page":"2482","DOI":"10.1056\/NEJMoa1205624","volume":"367","author":"ET Investigators","year":"2012","unstructured":"Investigators, E. T. et al. Effect of cinacalcet on cardiovascular disease in patients undergoing dialysis. N. Engl. J. Med. 367, 2482\u20132494 (2012).","journal-title":"N. Engl. J. Med."},{"key":"87_CR123","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1161\/CIRCULATIONAHA.114.013876","volume":"132","author":"SM Moe","year":"2015","unstructured":"Moe, S. M. et al. Cinacalcet, fibroblast growth factor-23, and cardiovascular disease in hemodialysis: the evaluation of cinacalcet HCl therapy to lower cardiovascular events (EVOLVE) trial. Circulation 132, 27\u201339 (2015).","journal-title":"Circulation"},{"key":"87_CR124","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1002\/jbmr.1923","volume":"28","author":"M Wolf","year":"2013","unstructured":"Wolf, M., Koch, T. A. & Bregman, D. B. Effects of iron deficiency anemia and its treatment on fibroblast growth factor 23 and phosphate homeostasis in women. J. Bone Miner. Res. 28, 1793\u20131803 (2013).","journal-title":"J. Bone Miner. Res."}],"container-title":["Nature Reviews Nephrology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/s41581-018-0087-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41581-018-0087-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41581-018-0087-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,20]],"date-time":"2023-05-20T22:07:53Z","timestamp":1684620473000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41581-018-0087-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,12,4]]},"references-count":124,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2019,2]]}},"alternative-id":["87"],"URL":"https:\/\/doi.org\/10.1038\/s41581-018-0087-2","relation":{},"ISSN":["1759-5061","1759-507X"],"issn-type":[{"value":"1759-5061","type":"print"},{"value":"1759-507X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,12,4]]},"assertion":[{"value":"4 December 2018","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The author declares no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}